Evidence map›Paper›PMID 39472678›Full record

ArticleGene therapy2025

Electroporation-mediated novel albumin-fused Flt3L DNA delivery promotes cDC1-associated anticancer immunity.

Ming-Hung Hu, Darrell Fan, Hsin-Fang Tu, Ya-Chea Tsai, Liangmei He, Zhicheng Zhou, Michelle Cheng, Deyin Xing, Suyang Wang, Alexis Wu and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ming-Hung HuDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Darrell FanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hsin-Fang TuDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ya-Chea TsaiDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Liangmei HeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Zhicheng ZhouDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michelle ChengDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Deyin XingDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Suyang WangDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Alexis WuDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
T C WuDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-1623-4584
Chien-Fu HungDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. chung2@jhmi.edu.ORCID 0000-0001-9170-7797

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI WARNER KING HUH, TZYY-CHOOU WU · 2003 to 2026
$53.5M
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer ImmunotherapyR01CA237067 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2019 to 2023
$2.9M
Albumin-FMS-like tyrosine kinase 3 ligand (Alb-Flt3L) fusion protein as a novel adjuvant to enhance the immunogenicity and therapeutic and prophylactic efficacies of a HPV protein vaccineR21CA234516 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2020 to 2021
$421k
Novel strategy combined with targeted radiation therapy unleashes potentantitumor immunity in HPV + head and neck cancerR21CA256020 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2021 to 2022
$417k
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1R21CA234516-01A1U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P50CA098252U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA237067U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R21CA256020U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R21DE029910-01
6 · The paper itself

Abstract

Dendritic cells (DCs) constitute a distinct type of immune cell found within tumors, serving a central role in mediating tumor antigen-specific immunity against cancer cells. Frequently, DC functions are dysregulated by the immunosuppressive signals present within the tumor microenvironment (TME). Consequently, DC manipulation holds great potential to enhance the cytotoxic T cell response against cancer diseases. One strategy involves administering Fms-like tyrosine kinase receptor 3 ligand (Flt3L), a vitally important cytokine for DC development. In this current study, the electroporation-mediated delivery of a novel albumin-fused Flt3L DNA (alb-Flt3L DNA) demonstrated the ability to induce an anti-tumor immune response. This albumin fusion construct possesses more persistent bioactivity in targeted organs. Furthermore, TC-1-bearing-C57BL/6 mice receiving alb-Flt3L DNA treatment presented better tumor control and superior survival. Cellular analysis revealed that alb-Flt3L DNA administration promoted robust DC and cDC1 expansion. In addition, increased levels of IFN-γ-secreting CD8

Indexed as

AlbuminsDendritic CellsMembrane ProteinsNeoplasmsAnimalsCD8-Positive T-LymphocytesCell Line, TumorElectroporationFemaleGenetic TherapyGene Transfer TechniquesHumansMiceMice, Inbred C57BLTumor MicroenvironmentAlbuminsflt3 ligand proteinMembrane Proteins

Identifiers

PMID39472678

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.